{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:03Z","timestamp":1753891263860,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is a rare systemic autoimmune disease associated with a high rate of mortality attributable to rapidly progressive interstitial lung disease. MDA5-positive DM is often complicated by a typical rash and muscle weakness. Herein, we describe a 50-year-old woman who presented with worsening pulmonary symptoms with an absence of typical clinical characteristics. We also review the treatments and prognosis made in similar cases, highlighting that closer attention should be paid to patients presenting with atypical DM, particularly when clinical manifestations such as rash and muscle weakness are not apparent.<\/jats:p>","DOI":"10.3389\/fmed.2024.1482350","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:20:28Z","timestamp":1734330028000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MDA5-positive dermatomyositis without muscle weakness and rash: a case report and literature review"],"prefix":"10.3389","volume":"11","author":[{"given":"Ping-Ping","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Gao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"152511","DOI":"10.1016\/j.semarthrit.2024.152511","article-title":"Mortality risk in patients with anti-MDA5 antibody-positive dermatomyositis: a risk assessment","volume":"69","author":"Kawada","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","article-title":"Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis","volume":"61","author":"So","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/03009742.2017.1340512","article-title":"Anti-MDA5-positive dermatomyositis: an emerging entity with a variable clinical presentation","volume":"46","author":"Ortiz-Santamaria","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","article-title":"Evaluation of clinical prognostic factors for interstitial pneu-monia in anti-MDA5 antibody-positive dermatomyositis patients","volume":"28","author":"Fujiki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00296-019-04255-2","article-title":"Liver dysfunction in anti-melanoma differentia-tion-associated gene 5 antibody-positive patients with dermatomyositis","volume":"39","author":"Nagashima","year":"2019","journal-title":"Rheumatol Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","article-title":"The characteristics of lymphocytes in patients positive for an-ti-MDA5 antibodies in interstitial lung disease","volume":"59","author":"Huang","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"152231","DOI":"10.1016\/j.semarthrit.2023.152231","article-title":"Risk factors for mortality in patients with anti-MDA5 anti-body-positive dermatomyositis: a meta-analysis and systematic review","volume":"62","author":"Xie","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1189\/jlb.4MR0617-223R","article-title":"The role of MDA5 in the development of autoimmune disease","volume":"103","author":"Sadler","year":"2018","journal-title":"J Leukoc Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e234946","DOI":"10.1136\/bcr-2020-234946","article-title":"Interstitial pneumonia with autoimmune features in a patient with melanoma differenti-ation-associated gene 5 (MDA5) antibody","volume":"13","author":"Hong","year":"2020","journal-title":"BMJ Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e940251","DOI":"10.12659\/MSM.940251","article-title":"Risk prediction for rapidly progressive interstitial lung disease in anti-MDA5-positive Der-matomyositis: the CRAFT model","volume":"29","author":"Guo","year":"2023","journal-title":"Med Sci Monit"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"908365","DOI":"10.3389\/fmed.2022.908365","article-title":"A new predictive model for the prognosis of MDA5(+) DM-ILD","volume":"9","author":"Niu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/crj.13616","article-title":"Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease","volume":"17","author":"Li","year":"2023","journal-title":"Clin Respir J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1093\/rheumatology\/kead117","article-title":"IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.55563\/clinexprheumatol\/g4l70r","article-title":"Anti-MDA5-positive dermatomyositis and remission in a single referral Centre population","volume":"41","author":"Tiniakou","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/art.42150","article-title":"Performance of the 2017 European Alliance of associations for Rheuma-tology\/American College of Rheumatology Classification Criteria in patients with idiopathic inflammatory myopathy and an-ti-melanoma differentiation-associated protein 5 positivity","volume":"74","author":"So","year":"2022","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12969-022-00723-5","article-title":"Successful rituximab treatment for severe rapidly progres-sive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review","volume":"20","author":"Nishi","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1093\/rheumatology\/keac084","article-title":"Good efficacy achieved by baricitinib in the treatment of an-ti-MDA5 antibody-positive dermatomyositis with alopecia areata","volume":"61","author":"Chen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.1097\/RHU.0000000000001460","article-title":"Concurrent treatment with rituximab and plasma ex-change for rapidly progressive interstitial lung disease complicating anti-MDA5 antibody-positive juvenile Dermatomyositis","volume":"27","author":"Shimizu","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in in-terstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive Dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2169\/internalmedicine.1410-22","article-title":"Early initiation of plasma exchange therapy for anti-MDA5(+) Dermatomyositis with refractory rapidly progressive interstitial lung disease","volume":"63","author":"Sasaki","year":"2023","journal-title":"Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with Daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive Dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1002\/iid3.897","article-title":"Case report: successful treatment of anti-MDA5-positive to negative dermatomyo-sitis-associated interstitial lung disease with the JAK inhibitor tofacitinib","volume":"11","author":"Jiang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41584-023-00939-z","article-title":"Co-trimoxazole reduces mortality in anti-MDA5-DM","volume":"19","author":"Phillips","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e56983","DOI":"10.7759\/cureus.56983","article-title":"The balance between intensive and palliative Care in an Anti-melanoma Differentia-tion-Associated Gene 5 (MDA5) antibody-positive acute interstitial pneumonia in a nonagenarian: a case report","volume":"16","author":"Asano","year":"2024","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e240046","DOI":"10.1136\/bcr-2020-240046","article-title":"Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases","volume":"14","author":"Mehta","year":"2021","journal-title":"BMJ Case Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fmed.2020.00077","article-title":"Interstitial lung disease-complicated an-ti-MDA5 antibody in clinically Amyopathic Dermatomyositis patients: report of two cases with distinct clinical features","volume":"7","author":"Pacot","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.rmcr.2019.01.012","article-title":"Anti-MDA5 antibody-positive rapidly progressive in-terstitial pneumonia without cutaneous manifestations","volume":"26","author":"Aoyama","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2169\/internalmedicine.1516-18","article-title":"Clinical features of anti-MDA5 anti-body-positive rapidly progressive interstitial lung disease without signs of Dermatomyositis","volume":"58","author":"Sakamoto","year":"2019","journal-title":"Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung dis-ease due to anti-MDA5 antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonzalez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2169\/internalmedicine.55.5774","article-title":"Radiological and pathological correlation in an-ti-MDA5 antibody-positive interstitial lung disease: rapidly progressive Perilobular opacities and diffuse alveolar damage","volume":"55","author":"Chino","year":"2016","journal-title":"Intern Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1482350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:20:30Z","timestamp":1734330030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1482350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":32,"alternative-id":["10.3389\/fmed.2024.1482350"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1482350","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1482350"}}